    Robert Greenberg | Second Sight Medical Products , Inc. | ZoomInfo.com
Greenberg Traurig Attorneys Robert J. Herrington, Philip M. Hymanson, and Gretchen N. Miller to Present/Moderate at DRI’s Product Liability Conference 




























PRWeb
Home
News Center
Blog



United States
United Kingdom
France

			Login
		
			Create a free account
		




RSS


Email Newsletters


Put PRWeb on your site




Greenberg Traurig Attorneys Robert J. Herrington, Philip M. Hymanson, and Gretchen N. Miller to Present/Moderate at DRI’s Product Liability Conference



Share Article

















Greenberg Traurig Attorneys Robert J. Herrington, Philip M. Hymanson, and Gretchen N. Miller to Present/Moderate at DRI’s Product Liability Conference






Los Angeles (PRWEB)
March 14, 2013
 Robert J. Herrington, Co-Chair of the firm’s Products Liability & Mass Torts practice and shareholder in the Los Angeles office and Philip M. Hymanson, Litigation shareholder in the Las Vegas office will be speaking at DRI’s Product Liability Conference, titled “Product Liability: Make Your Products Practice Bloom” in National Harbor, Maryland on April 3rd-5th. Herrington will be presenting on the topic of “Mitigating the Risks of Product Liability and Class Action Litigation,” and Hymanson will be presenting on the topic of “Avoiding the Landmines with your 30(b)(6) Witness.” As Chair of DRI’s Manufacturer’s Risk Prevention SLG, Gretchen N. Miller, Litigation and Products Liability & Mass Torts shareholder in the Chicago office, will also be moderating the Manufacturer’s Risk Prevention Breakout Program at the Conference.  All three presentations will take place on April 4, 2013.
According to DRI, the program will help attendees learn the latest trends and decisions affecting product liability cases. Regulators from the NTSB, NHTSA, and CPSC, along with manufacturers and lawyers who navigate these agencies regularly, will discuss best practices for minimizing liability before and during litigation. Experienced professionals will demonstrate voir dire, story theme development, and closing arguments in an interactive format. Offering 18 hours of CLE credit, attendees will receive valuable practice tips, strategies, and trial techniques to gain an advantage in defending modern product liability cases.
Herrington’s practice focuses on defending companies facing significant class action and products liability lawsuits in the areas of advertising, unfair competition, consumer products, consumer electronics, privacy, food & beverage, financial services, and insurance. Herrington is the author of a best-selling book titled, Verdict for the Defense (Sutton Hart Press 2011), which provides a blueprint for business leaders to defend their companies against the growing risk of mass action and class action liability. Herrington is based in the firm’s Los Angeles office.
Hymanson's practice focuses on complex commercial litigation, products liability, pharmaceuticals, medical devices and construction law. He is also experienced in health care, medical malpractice and white collar criminal matters. Hymanson is based in the firm’s Las Vegas office.
Miller concentrates her practice on complex commercial litigation, including product liability litigation, in state and federal courts. She also has significant experience in matters involving issues such as misappropriation of trade secrets, restrictive covenants, contract disputes and professional negligence. In addition to her litigation practice, Miller spends a good portion of her time counseling manufacturers, distributors and retailers regarding consumer product safety issues. Her practice includes counseling clients on compliance with the Consumer Product Safety Act, representing clients before the Consumer Product Safety Commission and various state attorneys general on consumer product safety issues, and providing guidance with recalls and recall procedures. Miller is based in the firm’s Chicago office.
Greenberg Traurig’s Products Liability & Mass Torts practice was recently recognized in the 2010 edition of the Chambers and Partners USA Guide, an annual listing of the leading business lawyers and law firms in the world, and in the 2010 edition of Legal 500: United States. 
About Greenberg Traurig, LLP
Greenberg Traurig, LLP is an international, full-service law firm with approximately 1750 attorneys serving clients from 35 offices in the United States, Latin America, Europe, the Middle East and Asia. In the U.S., the firm has more offices than any other among the Top 10 on The National Law Journal's 2012 NLJ 250. For additional information, please visit http://www.gtlaw.com.



Share article on socal media or email:









View article via:
											Pdf
										
											Print
										






Contact Author

Linda Aschettino
Greenberg Traurig LLP + 1 617-310-6000
				Email >
			


									Visit website
								




News Center




Robert J.  Greenberg - CEO, founder, businessman - profile

















directorpedia.net - List of CEOs, founders, board members and company directors











Robert J.  Greenberg
Check out list of companies and businesses related to Robert J.  Greenberg. Find out Robert J.  Greenberg address and contact details. View other people related to Robert J.  Greenberg - coworkers, colleagues, companions, etc.
Address:   

12744 SAN FERNANDO ROAD, BLDG. 3  SYLMAR 91342 CA




Companies related to Robert J.  Greenberg
CIKCompany NamePositionCompany Address0001266806SECOND SIGHT MEDICAL PRODUCTS INCChairman of Board 12744 SAN FERNANDO ROAD, BLDG. 3  SYLMAR 913420001625101Pulse Biosciences, Inc.Director 3957 POINT EDEN WAY  HAYWARD 94545




Robert J.  Greenberg on the Web
Persons related to Robert J.  Greenberg - SECOND SIGHT MEDICAL PRODUCTS INCNamePositionCityMendelsohn  AaronSylmarMENDELSOHON  AARONSYLMARAlfred E. Mann Living Trust10% Owner SYLMARMann  AlfredSylmarBRIAN G  ATWOODSAN FRANCISCOBradley J PhD  BolzonSAN FRANCISCOSAMUEL D  COLELLASAN FRANCISCOGregoire  CosendaiVP of European Operations SYLMARRobert J.  GreenbergChairman of Board SYLMARRobert J.  GreenbergChief Executive Officer SYLMARWilliams  GreggSylmarWILLILAMS  GREGGSYLMARIncumed, LLCSYLMARDavid Murray  JacquesSYLMARROSS A MD  JAFFESAN FRANCISCOLondon  KathySylmarWILLIAM J PHD  LINKDirector SANTA ANAWILLIAM J PHD  LINKSAN FRANCISCOBARBARA N  LUBASHSAN FRANCISCOALFRED E  MANNDirector VALENCIAALFRED E  MANNSYLMARJonathan Will  McGuireChief Executive Officer COLORADO SPRINGSBrian Vernon  MechSYLMARAaron  MendelsohnDirector SYLMARAaron  MendelsohnDirector SANTA MONICADONALD B  MILDERSAN FRANCISCOTHOMAS B  MILLERChief Financial Officer CALABASASTHOMAS B  MILLERSYLMARJohn Anthony  MosesCommercial VP Americas SYLMARSTEPHEN D  OKLANDCommercial VP, North America HOPKINTONMATTHEW J  PFEFFERDirector SOUTH SAN FRANCISCOEdward David  RandolphVice President of Manufacturin SYLMARAnne-Marie Juliette  RipleyVP of Regulatory Affairs SYLMARGreenberg  RobertSylmarREBECCA B  ROBERTSONSAN FRANCISCOFOGARTY  TOMSYLMARFogerty  TomSylmarVersant Affiliates Fund II-A, LPSAN FRANCISCOVersant Side Fund II, LPSAN FRANCISCOVersant Venture Capital II, LPSAN FRANCISCOVersant Ventures II LLCSAN FRANCISCOCharles M  WardenSAN FRANCISCOLink  WilliamSylmarGregg  WilliamsDirector SYLMARPersons related to Robert J.  Greenberg - Pulse Biosciences, Inc.NamePositionCityWang  AmySanta MonicaDow  BrianBurlingameMarlett  ChristopherSanta MonicaUecker  DarrinBurlingameBrian B  DowCFO & SVP Admin. and Finance SEATTLEROBERT W  DUGGAN10% Owner Robert J.  GreenbergDirector SYLMARROBERT  LEVANDEDirector MALVERNMitchell E.  LevinsonDirector BURLINGAMEZanganeh  MakyBurlingameMark & Tammy Strome Family TrustSANTA MONICALevinson  MitchellBurlingameNewBEM Corp.MILLBRAEDominion University Research Foundation  OldNORFOLKGreenberg  RobertBurlingameLevande  RobertSanta MonicaLevande  RobertBurlingameThierry B.  ThaureDirector BURLINGAMEThaure  ThierryBurlingameDARRIN  UECKERCEO and President MOUNTAIN VIEWMaky  ZanganehDirector SUNNYVALE












 












Robert J. Kirshenberg | Professionals | Greenberg Traurig LLP

































                Robert J. Kirshenberg
            
Shareholder
kirshenbergr@gtlaw.com



New York

D
+1 212.801.2186


T
+1 212.801.9200







vCard
PDF
Print
Share +



































Profile


Robert J. Kirshenberg focuses his practice on defending product liability actions in federal and state courts around the country.  He has represented numerous defendants in the field, including Fortune 500 and Fortune 100 companies, and has led and coordinated trial teams from the inception of an action to verdict and appeal. He has served as coordinating trial counsel for dozens of cases litigated simultaneously in multiple jurisdictions. He also regularly litigates a wide range of commercial litigation matters, in both court and arbitral fora. Robert's clients include public and private companies and individuals, restaurant developers along with individual entrepreneurs confronting business disputes in the United States and abroad.


Concentrations

Product liability
Complex civil litigation
Securities litigation
Consumer litigation
Privacy litigation



Read More +


Capabilities


Litigation




Experience















Representative Matters





Trial through verdict of numerous product liability actions.
Representation and counseling of a national retail chain in commercial actions pending across the country.
Representation and counseling of restaurant developers and owners.
Representation of multiple investment firms, brokers and brokerage houses in defense of SEC, NYSE and SRO investigations and customer brought arbitrations.







Recognition & Leadership



Awards & Accolades





Team Member, Law360 "Product Liability Practice Group of the Year" (2011)






Professional & Community Involvement





Member, American Bar Association
Member, New York State Bar Association
National Kidney Foundation
The Rogosin Institute
The Savin Foundation







Credentials



Education


J.D., Harvard Law School, 1989                                                

M.A., International Economics and Latin American Studies, Johns Hopkins UniversitySchool of Advanced International Studies 

B.A., International Economics and Latin American Studies, Johns Hopkins University                                                



Admissions


New York                                                    

Connecticut                                                    

U.S. District Court for the Eastern District of New York                                                    

U.S. District Court for the Southern District of New York                                                    

U.S. Court of Appeals for the Second Circuit                                                    

Languages


Spanish
                                                    







Quick Links





EXPAND ALL














Greenberg Traurig Attorneys to Speak at Natural Products Expo West 





























PRWeb
Home
News Center
Blog



United States
United Kingdom
France

			Login
		
			Create a free account
		




RSS


Email Newsletters


Put PRWeb on your site




Greenberg Traurig Attorneys to Speak at Natural Products Expo West



Share Article

















Greenberg Traurig Shareholders Robert J. Herrington, Patricia A. Leonard and Justin J. Prochnow will discuss strategies for handling food labeling class action litigation during a panel discussion at the Natural Products Expo West.






(PRWEB)
March 05, 2015
 Greenberg Traurig Shareholders Robert J. Herrington, Patricia A. Leonard and Justin J. Prochnow will discuss strategies for handling food labeling class action litigation during a panel discussion at the Natural Products Expo West.
The Exhibitor Education Session, “Labeling Litigation: Strategies for Marketing Products While Avoiding the Courtroom,” hosted by Greenberg Traurig, will take place Saturday, March 7, in Anaheim, California. Herrington, Leonard and Prochnow will provide strategies for companies based on their experience defending such claims.
The session will discuss:
     Top claims being targeted with class action lawsuits, such as the rise in claims over the use of the terms “all natural” or “healthy,” nutrient content claims, weight loss claims and general false/unsubstantiated claims
    Claims where companies face the biggest potential risk
    What a company should do if it gets a letter from a plaintiff’s lawyer – pre-litigation negotiation
At Greenberg Traurig, Herrington, a Shareholder in the Los Angeles office, serves as Co-Chair of the firm's Products Liability & Mass Torts Practice. Herrington focuses his practice on defending consumer products companies in complex, multi-party litigation, including class actions, government enforcement litigation, product defect litigation and mass torts.
Leonard, a Shareholder in the firm’s West Palm Beach Litigation Practice, focuses her practice on complex business and commercial litigation matters in state and federal courts, and in arbitration. Her broad experience includes matters involving breach of contract, employment discrimination defense, pharmaceutical and nutraceutical litigation, and food labeling litigation.
Prochnow, a Shareholder in the Denver Litigation Practice, concentrates his practice on regulatory and business issues primarily in the food, medical device, drug and cosmetic industries. Prochnow works with dietary supplement, sports nutrition, beverage, conventional food, cosmetic, medical device and over the counter drug companies to ensure regulatory compliance with statutes and regulations enforced by the Food and Drug Administration, Federal Trade Commission and other regulatory agencies. Prochnow will also moderate the panel discussion, “Defining ‘Natural’: Who gets to decide?” on Thursday, March 5.
About Greenberg Traurig’s Food & Beverage Group
Greenberg Traurig’s Food & Beverage Group, led by Shareholders Rick Shackelford, Robert Herrington and Justin Prochnow, offers a multidisciplinary team with significant experience in the food and beverage industry. This includes advising clients on US and International issues relating to: corporate product development; product labeling; promotions and advertising; federal consumer class actions; the Food and Drug Administration (FDA); food safety and recall issues; commercial contracts and distribution contracts; intellectual property issues including brand protection and management, patent and trademark disputes; competitor false advertising (Lanham Act) claims; regulatory and legislative issues; tax issues; and consumer class actions brought under various states’ consumer protection laws, including litigious and challenging jurisdictions, like California with its unfair competition law (UCL) false advertising law (FAL) and Consumer Legal Remedies Act (CLRA) and Florida with its uniform deceptive trade practices act (FDUTPA). Our team also has experience in state regulatory work.
About Greenberg Traurig, LLP
Greenberg Traurig, LLP is an international, multi-practice law firm with approximately 1800 attorneys serving clients from 37 offices in the United States, Latin America, Europe, Asia, and the Middle East. The firm is among the “Power Elite” in the 2014 BTI Client Relationship Scorecard report, which assesses the nature and strength of law firms' client relationships. For additional information, please visit http://www.gtlaw.com.



Share article on social media or email:









View article via:
											Pdf
										
											Print
										






Contact Author

Elaine Walker
Greenberg Traurig +1 305.579.0832
				Email >
			


									Visit website
								




News Center




Robert J. Greenberg M.D., Ph.D.: Executive Profile & Biography - Bloomberg









































  





















































































July 28, 2017 8:48 PM ET
Healthcare Equipment and Supplies

Company Overview of Second Sight Medical Products, Inc.



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Robert J. Greenberg M.D., Ph.D.Chairman, Second Sight Medical Products, Inc.AgeTotal Calculated CompensationThis person is connected to 2 Board Members in 2 different organizations across 2 different industries.See Board Relationships49$608,065As of Fiscal Year 2016
Background

		Dr. Robert J. Greenberg, M.D., Ph.D. served as the Chief Executive Officer and President at Second Sight Medical Products, Inc. until August 18, 2015. Dr. Greenberg worked co-managing the Alfred E. Mann Foundation. From 1997 to 1998, he served as a Medical Officer and Lead Reviewer for IDEs and 510(k)s at the Office of Device Evaluation at the U.S. Food and Drug Administration in the Neurological Devices Division. He also has biosensor and microsensor fabrication experience ... from work and teaching at the Whittaker Sensors Laboratory at Johns Hopkins. He has started several other small companies including one called 'Campus Security' where he designed, manufactured and marketed an electronic intercom security system called TELEKEY®. He has been the Chairman of Second Sight Medical Products, Inc. since August 18, 2015 and serves as its Director. Dr. Greenberg serves on the Board of directors of the Southern California Biomedical Council and the Alfred E. Mann Foundation. He has been a Director of Pulse Biosciences, Inc. since May 2015. He served as an Associate Director of the Alfred Mann Institute at USC and Adjunct Professor at UCLA. From 1991 to 1997, he conducted animal and human trials demonstrating the feasibility of retinal electrical stimulation in patients with Retinitis Pigmentosa. This work was done at the Wilmer Eye Institute at The Johns Hopkins Hospital in Baltimore and led to the granting of his Ph.D. in 1997 from the Johns Hopkins Biomedical Engineering Department. In 1998, he received his Medical Degree from The Johns Hopkins School of Medicine. Dr. Greenberg received a B.S. in Electrical and Biomedical Engineering from Duke University in 1990 and a degree in Technical Electronics from Nassau Technical Institute in 1985.Read Full Background




Corporate Headquarters
12744 San Fernando RoadSylmar, California 91342United StatesPhone: 818-833-5000Fax: 818-833-5067
Board Members Memberships
1998-PresentChairmanSecond Sight Medical Products, Inc.2015-PresentDirectorPulse Biosciences, Inc.
Education
Bachelor's Degree Duke University
Other Affiliations
Duke UniversityPulse Biosciences, Inc.


Annual Compensation
Salary$394,000Bonus$86,680Total Annual Compensation$480,680
Stocks Options
All Other Compensation$13,410Exercisable Options$785,769Unexercisable Options$311,766Total Number of Options$1,097,535
Total Compensation
Total Annual Cash Compensation$494,090Total Short Term Compensation$480,680Other Long Term Compensation$13,410Total Calculated Compensation$608,065




Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONThere is no Competitor Compensation data available.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Second Sight Medical Products, Inc., please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close
































Robert J. Greenberg - Eye on the Cure
























    



Skip to Content




















HomeAbout
Contact
Foundation Website





Robert J. Greenberg
Robert J. Greenberg, MD, PhD, is co-founder as well CEO and President of Second Sight Medical Products, Inc., which is located in Sylmar, California.





The following articles were authored by Robert J. Greenberg




How an FDA-Approved Retinal Prosthesis Came To Be


By Robert J. Greenberg on February 14, 2013 | 40 Comments


The Argus II Retinal Prosthesis System was recently granted market approval by the U.S. Food and Drug Administration (FDA), which marks a significant milestone in the development of a therapy that has spanned more than 20 years. It was at Johns Hopkins University, in the early 1990s, that I, along with Drs. de Juan, Humayun and Dagnelie, with some early support from FFB, carried out the very first short-term (one hour or so) experiments with human volunteers. We demonstrated that electrical stimulation of the retina could, indeed, produce spots of light perceived by blind patients.
 Continue Reading…








 




Regular Contributors 






Dr. Steve RoseSteve is highly respected for his expertise and tireless commitment to finding treatments and cures for vision-robbing retinal diseases. Read More...
Ben ShabermanAs the Foundation's Director, Science Communica- tions, Ben writes science and research articles for the Foundation’s website, newsletters and Eye on the Cure blog. Read More...


Want to hear from the Foundation? The Foundation Fighting Blindness provides valuable disease information, research updates, low vision resources, and networking opportunities to help you stay informed. Sign up to receive our newsletter and other valuable emails:


Categories 
VISIONS 2014 (4)

Pop Culture (2)

In Their Own Words (1)

Prevention (2)

VISIONS 2015 (6)

VISIONS 2016 (5)

General (129)

Research (202)

Gene Therapy (74)

Stem Cell (47)

Pharmaceuticals (39)

Genetics (36)

Prosthetics (35)



Diseases (205)

AMD (71)

Retinitis pigmentosa (110)

Stargardt disease (63)

Usher syndrome (75)

LCA (59)

Other diseases (58)



Support (59)

News Commentary (23)

FFB on the Road (63)

VISIONS 2013 (8)

VISIONS (12)



Guest Bloggers (22)

Reader Questions Answered (2)

The Challenge (4)








Home | 
					About | Contact | 
					Foundations Website | 
					Donate | 
					Meet Dr. Steve Rose | 
					Comment Policy | 
					Site Map
Medical Disclaimer:The information contained on the Foundation Fighting Blindness web site and other online properties including Eye on the Cure is provided for your general information only. The Foundation does not give medical advice or engage in the practice of medicine. Physicians differ in their approach to incorporating research results into their clinical practice. You should always consult with and be guided by your Physician’s advice when considering treatment based on research results.

All information and content on this web site are protected by copyright. 















Robert J. Herrington | Professionals | Greenberg Traurig LLP




























                Robert J. Herrington
            
Shareholder
herringtonr@gtlaw.com



Los Angeles

D
+1 310.586.7816


T
+1 310.586.7700







vCard
PDF
Print
Share +



































Profile


Robert J. Herrington is Co-Chair of the firm's Products Liability & Mass Torts Practice. He focuses his practice on defending consumer products companies in complex, multi-party litigation, including class actions, government enforcement litigation, product defect litigation and mass torts. Rob represents companies in a variety of industries, including apparel and footwear, retail, emerging technologies, consumer electronics, video game, telecommunications, advertising and publicity, online retailing, food and beverage, nutritional supplements, personal care products, sports and fitness, outdoor equipment, home appliances, automotive, and insurance.


Rob is the author of the best-selling book, Verdict for the Defense (Sutton Hart Press 2011), and a co-author of The Class Action Fairness Act: Law and Strategy (ABA Publishing 2013). In 2013, 2014 and 2015, Rob was named in Law360's list of "Top Attorneys Under 40" for Class Actions.
Concentrations

Consumer class actions
Consumer protection litigation
Product defect litigation
False advertising
Unfair and deceptive trade practices
California Business & Professions Code § 17200
Consumer Legal Remedies Act
Products liability and mass torts
Complex commercial litigation
Trials



Read More +


Capabilities


Litigation
Class Action Litigation
Products Liability & Mass Torts 
Appellate
Cybersecurity, Privacy & Crisis Management
Emerging Technology
Anti-Counterfeiting




Experience















Representative Matters





Won summary judgment for a Fortune 50 retailer in a class action lawsuit alleging false and deceptive business practices in connection with the sale of oil change services.
Obtained complete dismissal of a putative class action against fire alarm manufacturer alleging safety defects and false advertising.
Obtained dismissal of putative class action against major brokerage firm alleging securities fraud and breach of fiduciary duty in connection with margin trading.  Dismissal affirmed by Ninth Circuit.
Obtained dismissal of a putative class action against a clothing manufacturer alleging products were mislabeled as “Made in the USA.”
Defeated class certification in case against Fortune 50 retailer alleging that asset protection employees were misclassified as managers.
Obtained dismissal of two putative class actions against alcoholic beverage manufacturer alleging product was not "all natural."
Obtained dismissal at the pleading stage of a putative nationwide class action against five major movie studios challenging the marketing of Blu-ray movies.
Obtained dismissal at the pleading stage of a putative class action against one of the largest video game studios claiming that product suffered from various defects and missing functionality.
Obtained dismissal at the pleading stage of a putative class against a Fortune 50 retailer challenging the marketing of, and fees associated with, lead-acid batteries.
Obtained dismissal at the pleading stage of a securities fraud mass action against one of the world’s largest real estate investment firms involving tenant-in-common investments in commercial property.
Obtained dismissal at the pleading stage on behalf of a major telecommunications provider in lawsuit alleging violations of equal protection, civil rights and consumer protection laws.
Acted as lead trial counsel in defense of government contractor against RICO, fraud, and breach of contract lawsuit seeking eight-figure damage award. Zero damages awarded after trial.
Acted as trial counsel in defense of the co-founder of the Hard Rock Cafe against fraud and breach of fiduciary duty lawsuit seeking eight-figure damages award. Unanimous defense jury verdict.
Obtained dismissal at the pleading stage of a putative nationwide class action against a major telecommunications provider in lawsuit alleging violations of federal and state telecom and consumer protection laws.
Obtained dismissal at pleading stage of putative nationwide class action against online credit monitoring service in lawsuit alleging violations of federal consumer protection laws.
Obtained dismissal at the pleading stage of putative nationwide class action against one of the nation's leading Internet marketing companies in lawsuit alleging false advertising; dismissal affirmed on appeal.
Represented Fortune 50 pharmaceutical company in consolidated and multidistrict litigation involving alleged off-label use of various medications; secured dismissal of hundreds of cases.
Obtained dismissal at the pleading stage of a products liability wrongful death lawsuit against major telecommunications provider.
Obtained dismissal at the pleading stage of putative nationwide class action against Internet marketing company in lawsuit alleging false advertising and violations of consumer protection laws.
Obtained dismissal at the pleading stage of a putative class action against one of California’s largest automobile insurers challenging installment service fees and seeking a nine-figure recovery.
Defended the world’s fifth largest insurer in parallel class action and attorney general litigation challenging annuity sales practices.
Obtained dismissal at the pleading stage of a putative class action against one of the nation’s largest beverage manufacturers challenging recycling and other business practices; decision affirmed on appeal.
Obtained dismissal at the pleading stage of an unfair competition lawsuit against international cosmetics manufacturer.
Obtained dismissal at the pleading stage of an unfair competition/privacy case filed against major telecommunications company.
Obtained dismissal of a patent infringement lawsuit against leading explosives manufacturer after an early claim-construction ruling.
Obtained summary judgment on behalf of a major jewelry manufacturer in copyright infringement case.
Obtained summary judgment on behalf of major consumer electronics retailer in case alleging unfair competition and trademark infringement.
Obtained preliminary injunction on behalf of a major telecommunications provider in counterfeiting/trademark infringement case.
Prevailed before en banc panel of Ninth Circuit Court of Appeal in litigation involving Constitutional and privacy violations.







Recognition & Leadership



Awards & Accolades





Listed, Super Lawyers magazine, Southern California Super Lawyers, 2015-2016
    
"Rising Star," 2009-2014


Listed, Law360, "Rising Star," 2013-2015
    
Class Action, 2013-2015
Product Liability, 2013


Listed, The Legal 500 United States, 2013-2017, "Product Liability, Mass Tort and Class Action: Consumer Products"
Team Member, a Law360 "Food & Beverage Practice Group of the Year," 2015
Team Member, a Law360 "Products Liability Practice Group of the Year," 2011
Team Member, a Law360 "Appellate Practice Group of the Year," 2010






Professional & Community Involvement





Member, American Bar Association, Litigation Section
	
Member, Appellate Practice Committee
Member, Class Action and Derivative Suits Committee
		
Co-Editor, Class Action and Derivative Suits Committee Newsletter




Member, Century City Bar Association
Member, Association of Business Trial Lawyers Los Angeles
Member, International Bar Association
Member, Los Angeles County Bar Association







Credentials



Education


J.D., University of Colorado Law School
Order of the Coif 
Articles Editor, University of Colorado Law Review 
 

B.A., summa cum laude, University of DenverMember, Phi Beta Kappa 



Admissions


California                                                    

Colorado                                                    

Supreme Court of the United States                                                    

U.S. Court of Appeals for the Ninth Circuit                                                    

U.S. Court of Appeals for the Sixth Circuit                                                    

U.S. District Court for the Central District of California                                                    

U.S. District Court for the District of Colorado                                                    

U.S. District Court for the Northern District of California                                                    

U.S. District Court for the Southern District of California                                                    








News, Insights & Events


Rob is a contributor to the Consumer Products Counselor Blog , the GT L&E Blog , and is a frequent speaker and author on class actions and complex litigation topics.



Featured
News
Insights
Past Events







{{featureditem.Date}}

                                            {{featureditem.Type}}
                                        


{{featureditem.EntityTitle}}
{{featureditem.ReadTime}}





View More +










{{newsItem.Date}}

                                            {{newsItem.Type}}
                                        


{{newsItem.EntityTitle}}
{{newsItem.ReadTime}}





View More +










{{insightItem.Date}}

                                            {{insightItem.Type}}
                                        


{{insightItem.EntityTitle}}
{{insightItem.ReadTime}}





View More +










{{eventItem.Date}}

                                            {{eventItem.Type}}
                                        


{{eventItem.EntityTitle}}





View More +










{{eventItem.Date}}

                                            {{eventItem.Type}}
                                        


{{eventItem.EntityTitle}}





View More +







 
Quick Links





EXPAND ALL
















 SECGems: Greenberg Robert J. 







































  







			Data feeds now available
			Excel / CSV / Java / Python /etc 
Database
Learn more









  




  


  






























 Greenberg Robert J. 
		     










 Info




 Ownership




 Filings














←


 1 


→



 Ownership filings:    (1 of 14 - Total: 14)








Filing date
2017-06-07
Submission
 0001615774-17-003028.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 SECOND SIGHT MEDICAL PRODUCTS INC  EYES

Reporting Owner
 Greenberg Robert J.
[
				      
				        Director,  
				        Officer, 
				       Chairman of Board, 
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Non-Derriv. transCommon Stock2017-05-312017-05-314A : Grant / awardFalse130900.978A186001D
Non-Derriv. transCommon Stock2017-06-052017-06-054A : Grant / awardFalse130901.13D172911D
Derriv. holdingNon-Qualified Stock Option (right to buy)1.972018-01-032027-01-03256410Common Stock256410D
Derriv. holdingNon-Qualified Stock Option (right to buy)4.12017-01-212026-01-2157563Common Stock57563D
Derriv. holdingNon-Qualified Stock Option (right to buy)52009-02-012018-02-0123750Common Stock23750D
Derriv. holdingNon-Qualified Stock Option (right to buy)52009-11-012018-11-01150000Common Stock150000D
Derriv. holdingNon-Qualified Stock Option (right to buy)52010-02-012019-02-0133750Common Stock33750D
Derriv. holdingNon-Qualified Stock Option (right to buy)52011-02-012020-02-01103750Common Stock103750D
Derriv. holdingNon-Qualified Stock Option (right to buy)52012-03-012021-03-0141563Common Stock41563D
Derriv. holdingNon-Qualified Stock Option (right to buy)52013-03-012022-03-0138750Common Stock38750D
Derriv. holdingNon-Qualified Stock Option (right to buy)52015-04-012024-04-0146875Common Stock46875D
Derriv. holdingNon-Qualified Stock Option (right to buy)92015-09-262024-09-26414659Common Stock414659D
Derriv. holdingNon-Qualified Stock Option (right to buy)13.092016-03-252025-03-2531250Common Stock31250D












Filing date
2017-05-18
Submission
 0001209191-17-033568.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 Pulse Biosciences, Inc.  PLSE

Reporting Owner
 Greenberg Robert J.
[
				      
				        Director,  
				      
				      
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Derriv. transStock Option (right to buy)27.142017-05-164A : Grant / awardFalse150000.00A2017-07-012027-05-1615000Common Stock15000D












Filing date
2017-05-10
Submission
 0001209191-17-031418.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 Pulse Biosciences, Inc.  PLSE

Reporting Owner
 Greenberg Robert J.
[
				      
				        Director,  
				      
				      
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Non-Derriv. transCommon Stock2017-05-104M : Exer. or conv. of deriv. security exemptedFalse250002.67A25000D
Non-Derriv. transCommon Stock2017-05-104S : Open market or private saleFalse2218021.03D2820D
Non-Derriv. transCommon Stock2017-05-104S : Open market or private saleFalse282021.867D0D
Derriv. transStock Option (right to buy)2.672017-05-104M : Exer. or conv. of deriv. security exemptedFalse250000.00D2020-06-0150655Common Stock25000D












Filing date
2017-01-05
Submission
 0001615774-17-000044.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 SECOND SIGHT MEDICAL PRODUCTS INC  EYES

Reporting Owner
 Greenberg Robert J.
[
				      
				        Director,  
				        Officer, 
				       Chairman of Board, 
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Non-Derriv. holdingCommon Stock172911D
Derriv. transNon-Qualified Stock Option (right to buy)1.972017-01-034A : Grant / awardFalse256410A2018-01-032027-01-03256410Common Stock256410D
Derriv. holdingNon-Qualified Stock Option (right to buy)4.12017-01-212026-01-2157563Common Stock57563D
Derriv. holdingNon-Qualified Stock Option (right to buy)4.252014-01-012017-01-01125000Common Stock125000D
Derriv. holdingNon-Qualified Stock Option (right to buy)52008-01-012017-01-0130625Common Stock30625D
Derriv. holdingNon-Qualified Stock Option (right to buy)52009-02-012018-02-0123750Common Stock23750D
Derriv. holdingNon-Qualified Stock Option (right to buy)52009-11-012018-11-01150000Common Stock150000D
Derriv. holdingNon-Qualified Stock Option (right to buy)52010-02-012019-02-0133750Common Stock33750D
Derriv. holdingNon-Qualified Stock Option (right to buy)52011-02-012020-02-01103750Common Stock103750D
Derriv. holdingNon-Qualified Stock Option (right to buy)52012-03-012021-03-0141563Common Stock41563D
Derriv. holdingNon-Qualified Stock Option (right to buy)52013-03-012022-03-0138750Common Stock38750D
Derriv. holdingNon-Qualified Stock Option (right to buy)52015-04-012024-04-0146875Common Stock46875D
Derriv. holdingNon-Qualified Stock Option (right to buy)92015-09-262024-09-26414659Common Stock414659D
Derriv. holdingNon-Qualified Stock Option (right to buy)13.092016-03-252025-03-2531250Common Stock31250D












Filing date
2016-12-02
Submission
 0001615774-16-008701.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 SECOND SIGHT MEDICAL PRODUCTS INC  EYES

Reporting Owner
 Greenberg Robert J.
[
				      
				        Director,  
				        Officer, 
				       Chairman of Board, 
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Non-Derriv. transCommon Stock2016-12-012016-12-014S : Open market or private saleFalse19501.96D172911D
Derriv. holdingNon-Qualified Stock Option (right to buy)4.10002017-01-212026-01-2157563Common Stock57563D
Derriv. holdingNon-Qualified Stock Option (right to buy)4.25002014-01-012017-01-01125000Common Stock125000D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002008-01-012017-01-0130625Common Stock30625D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002009-02-012018-02-0123750Common Stock23750D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002009-11-012018-11-01150000Common Stock150000D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002010-02-012019-02-0133750Common Stock33750D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002011-02-012020-02-01103750Common Stock103750D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002012-03-012021-03-0141563Common Stock41563D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002013-03-012022-03-0138750Common Stock38750D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002015-04-012024-04-0146875Common Stock46875D
Derriv. holdingNon-Qualified Stock Option (right to buy)9.00002015-09-262024-09-26414659Common Stock414659D
Derriv. holdingNon-Qualified Stock Option (right to buy)13.09002016-03-252025-03-2531250Common Stock31250D












Filing date
2016-06-06
Submission
 0001615774-16-005788.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 SECOND SIGHT MEDICAL PRODUCTS INC  EYES

Reporting Owner
 Greenberg Robert J.
[
				      
				        Director,  
				        Officer, 
				       Chairman of Board, 
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Non-Derriv. transCommon Stock2016-06-022016-06-024S : Open market or private saleFalse85714.1000D172911D
Derriv. holdingNon-Qualified Stock Option (right to buy)4.10002017-01-212026-01-2157563Common Stock57563D
Derriv. holdingNon-Qualified Stock Option (right to buy)4.25002014-01-012017-01-01125000Common Stock125000D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002008-01-012017-01-0130625Common Stock30625D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002009-02-012018-02-0123750Common Stock23750D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002009-11-012018-11-01150000Common Stock150000D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002010-02-012019-02-0133750Common Stock33750D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002011-02-012020-02-01103750Common Stock103750D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002012-03-012021-03-0141563Common Stock41563D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002013-03-012022-03-0138750Common Stock38750D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002015-04-012024-04-0146875Common Stock46875D
Derriv. holdingNon-Qualified Stock Option (right to buy)9.00002015-09-262024-09-26414659Common Stock414659D
Derriv. holdingNon-Qualified Stock Option (right to buy)13.09002016-03-252025-03-2531250Common Stock31250D












Filing date
2016-05-13
Submission
 0001209191-16-119846.nc

Form
3  Ownership: Initial statement of beneficial ownership of securities. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 Pulse Biosciences, Inc.  PLSE

Reporting Owner
 Greenberg Robert J.
[
				      
				        Director,  
				      
				      
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Derriv. holdingStock Option (right to buy)2.672020-06-01Common Stock75655D












Filing date
2016-04-20
Submission
 0001615774-16-005043.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 SECOND SIGHT MEDICAL PRODUCTS INC  EYES

Reporting Owner
 Greenberg Robert J.
[
				      
				        Director,  
				        Officer, 
				       Chairman of Board, 
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Non-Derriv. transCommon Stock2016-04-184M : Exer. or conv. of deriv. security exemptedFalse82235.0000A181134D
Non-Derriv. transCommon Stock2016-04-184S : Open market or private saleFalse82235.2688D172911D
Derriv. transNon-Qualified Stock Option (right to buy)5.00002016-04-184M : Exer. or conv. of deriv. security exemptedFalse82230.00D2007-05-012016-05-010Common Stock8223D
Derriv. holdingNon-Qualified Stock Option (right to buy)4.10002017-01-212026-01-2157563Common Stock57563D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002008-01-012017-01-0130625Common Stock30625D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002009-02-012018-02-0123750Common Stock23750D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002009-11-012018-11-01150000Common Stock150000D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002010-02-012019-02-0133750Common Stock33750D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002011-02-012020-02-01103750Common Stock103750D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002012-03-012021-03-0141563Common Stock41563D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002013-03-012022-03-0138750Common Stock38750D
Derriv. holdingNon-Qualified Stock Option (right to buy)4.25002014-01-012017-01-01125000Common Stock125000D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002015-04-012024-04-0146875Common Stock46875D
Derriv. holdingNon-Qualified Stock Option (right to buy)9.00002015-09-262024-09-26414659Common Stock414659D
Derriv. holdingNon-Qualified Stock Option (right to buy)13.09002016-03-252025-03-2531250Common Stock31250D












Filing date
2016-01-25
Submission
 0001615774-16-003987.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 SECOND SIGHT MEDICAL PRODUCTS INC  EYES

Reporting Owner
 Greenberg Robert J.
[
				      
				        Director,  
				        Officer, 
				       President & CEO, 
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Non-Derriv. holdingCommon Stock172911D
Derriv. transNon-Qualified Stock Option (right to buy)4.10002016-01-214A : Grant / awardFalse57563A2017-01-212026-01-2157563Common Stock57563D
Derriv. holdingNon-Qualified Stock Option (right to buy)4.252008-01-012017-01-01125000Common Stock125000D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002007-05-012016-05-018223Common Stock8223D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002008-01-012017-01-0130625Common Stock30625D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002009-02-012018-02-0123750Common Stock23750D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002009-11-012018-11-01150000Common Stock150000D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002010-02-012019-02-0133750Common Stock33750D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002011-02-012020-02-01103750Common Stock103750D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002012-03-012021-03-0141563Common Stock41563D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002013-03-012022-03-0138750Common Stock38750D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002015-04-012024-04-0146875Common Stock46875D
Derriv. holdingNon-Qualified Stock Option (right to buy)9.00002015-09-262024-09-26414659Common Stock414659D
Derriv. holdingNon-Qualified Stock Option (right to buy)13.09002016-03-252025-03-2531250Common Stock31250D












Filing date
2015-12-09
Submission
 0001615774-15-003611.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 SECOND SIGHT MEDICAL PRODUCTS INC  EYES

Reporting Owner
 Greenberg Robert J.
[
				      
				        Director,  
				        Officer, 
				       Chairman, 
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Non-Derriv. transCommon Stock2015-12-072015-12-074M : Exer. or conv. of deriv. security exemptedFalse179694.7500A190880D
Non-Derriv. transCommon Stock2015-12-074S : Open market or private saleFalse179695.3000D172911D
Derriv. transNon-Qualified Stock Option (right to buy)4.75002015-12-072015-12-074M : Exer. or conv. of deriv. security exemptedFalse179695.3D2007-01-012016-01-010Common Stock17969D
Derriv. holdingNon-Qualified Stock Option (right to buy)4.25002008-01-012017-01-01125000Common Stock125000D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002007-05-012016-05-018223Common Stock8223D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002008-01-012017-01-0130625Common Stock30625D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002009-02-012018-02-0123750Common Stock23750D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002009-11-012018-11-01150000Common Stock150000D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002010-02-012019-02-0133750Common Stock33750D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002011-02-012020-02-01103750Common Stock103750D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002012-03-012021-03-0141563Common Stock41563D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002013-03-012022-03-0138750Common Stock38750D
Derriv. holdingNon-Qualified Stock Option (right to buy)5.00002015-04-012024-04-0146875Common Stock46875D
Derriv. holdingNon-Qualified Stock Option (right to buy)9.00002015-09-262024-09-26414659Common Stock414659D
Derriv. holdingNon-Qualified Stock Option (right to buy)13.09002016-03-252025-03-2531250Common Stock31250D












Filing date
2015-06-04
Submission
 0001615774-15-001372.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 SECOND SIGHT MEDICAL PRODUCTS INC  EYES

Reporting Owner
 Greenberg Robert J.
[
				      
				        Director,  
				        Officer, 
				       CHIEF EXECUTIVE OFFICER, 
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Non-Derriv. transCOMMON STOCK2015-06-024M : Exer. or conv. of deriv. security exemptedFalse781534.75A301187D
Non-Derriv. transCOMMON STOCK2015-06-024F : Pmt of exercise price or tax liabFalse2658613.96D275231D
Non-Derriv. transCOMMON STOCK2015-06-024S : Open market or private saleFalse7815313.96D197078D
Non-Derriv. transCOMMON STOCK2015-06-034M : Exer. or conv. of deriv. security exemptedFalse718474.75A268925D
Non-Derriv. transCOMMON STOCK2015-06-034F : Pmt of exercise price or tax liabFalse2416714.12D244758D
Non-Derriv. transCOMMON STOCK2015-06-034S : Open market or private saleFalse7184714.12D172911D
Derriv. transOption4.752015-06-024M : Exer. or conv. of deriv. security exemptedFalse781530A2015-09-0171847Common Stock78153D
Derriv. transOption4.752015-06-034M : Exer. or conv. of deriv. security exemptedFalse718470A2015-09-010Common Stock71847D
Derriv. holdingOption4.252017-01-01125000Common Stock125000D
Derriv. holdingOption4.752016-01-0117969Common Stock17969D
Derriv. holdingOption5.002016-05-018223Common Stock8223D
Derriv. holdingOption5.002017-01-0130625Common Stock30625D
Derriv. holdingOption5.002018-02-0130625Common Stock23750D
Derriv. holdingOption5.002018-11-01150000Common Stock150000D
Derriv. holdingOption5.002019-02-0133750Common Stock33750D
Derriv. holdingOption5.002020-02-0153125Common Stock53125D
Derriv. holdingOption5.002020-02-0150625Common Stock50625D
Derriv. holdingOption5.002021-03-0141563Common Stock41563D
Derriv. holdingOption5.002022-03-0129063Common Stock29063D
Derriv. holdingOption5.002024-04-0111719Common Stock11719D












Filing date
2015-03-24
Submission
 0001615774-15-000552.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 SECOND SIGHT MEDICAL PRODUCTS INC  EYES

Reporting Owner
 Greenberg Robert J.
[
				      
				        Director,  
				        Officer, 
				       CHIEF EXECUTIVE OFFICER, 
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Non-Derriv. transCOMMON STOCK2015-03-204S : Open market or private saleFalse9874213.28D224922D
Non-Derriv. transCOMMON STOCK2015-03-234S : Open market or private saleFalse125813.40D223664D
Derriv. holdingOption(b)4.252017-01-01125000Common Stock125000D
Derriv. holdingOption(c)4.752015-09-01150000Common Stock150000D
Derriv. holdingOption(d)4.752016-01-0117969Common Stock17969D
Derriv. holdingOption(e)5.002016-05-018223Common Stock8223D
Derriv. holdingOption(f)5.002017-01-0130625Common Stock30625D
Derriv. holdingOption(g)5.002018-02-0123750Common Stock23750D
Derriv. holdingOption(h)5.002018-11-01150000Common Stock150000D
Derriv. holdingOption(i)5.002019-02-0123750Common Stock23750D
Derriv. holdingOption(j)5.002020-02-0153125Common Stock53125D
Derriv. holdingOption(k)5.002020-02-0150625Common Stock50625D
Derriv. holdingOption(l)5.002021-03-0141563Common Stock41563D
Derriv. holdingOption(m)5.002022-03-0129063Common Stock29063D
Derriv. holdingOption(n)5.002024-04-0111718Common Stock11718D












Filing date
2015-01-05
Submission
 0001615774-15-000023.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 SECOND SIGHT MEDICAL PRODUCTS INC  EYES

Reporting Owner
 Greenberg Robert J.
[
				      
				        Director,  
				        Officer, 
				       Chief Executive Officer, 
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Non-Derriv. transCommon Stock2015-01-014M : Exer. or conv. of deriv. security exemptedFalse590634.75A363063D
Non-Derriv. transCommon Stock2015-01-014F : Pmt of exercise price or tax liabFalse2734410.26D335719D
Non-Derriv. transCommon Stock2015-01-014F : Pmt of exercise price or tax liabFalse1205510.26D323664D
Derriv. holdingOption(b)4.252017-01-01125000Common Stock125000D
Derriv. holdingOption(c)4.752015-09-01150000Common Stock150000D
Derriv. holdingOption(d)4.752016-01-0117969Common Stock17969D
Derriv. holdingOption(e)5.002016-05-018223Common Stock8223D
Derriv. holdingOption(f)5.002017-01-0130265Common Stock30265D
Derriv. holdingOption(g)5.002018-02-0123750Common Stock23750D
Derriv. holdingOption(h)5.002018-11-01150000Common Stock150000D
Derriv. holdingOption(i)5.002019-02-0133750Common Stock33750D
Derriv. holdingOption(j)5.002020-02-0153125Common Stock53125D
Derriv. holdingOption(k)5.002020-02-0150625Common Stock50625D
Derriv. holdingOption(l)5.002021-03-0141563Common Stock41563D
Derriv. holdingOption(m)5.002022-03-0129063Common Stock29063D












Filing date
2014-11-19
Submission
 0001615774-14-000369.nc

Form
3  Ownership: Initial statement of beneficial ownership of securities. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 SECOND SIGHT MEDICAL PRODUCTS INC  EYES

Reporting Owner
 Greenberg Robert J.
[
				      
				        Director,  
				        Officer, 
				       CEO & President, 
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Non-Derriv. holdingCommon Stock304000D
Derriv. holdingOption4.252017-01-01Common Stock125000D
Derriv. holdingOption4.752015-01-01Common Stock59063D
Derriv. holdingOption4.752015-09-01Common Stock150000D
Derriv. holdingOption4.752016-01-01Common Stock17969D
Derriv. holdingOption5.002016-05-01Common Stock8.223D
Derriv. holdingOption5.002017-01-01Common Stock30265D
Derriv. holdingOption5.002018-02-01Common Stock23750D
Derriv. holdingOption5.002018-11-01Common Stock150000D
Derriv. holdingOption5.002019-02-01Common Stock33750D
Derriv. holdingOption5.002020-02-01Common Stock53125D
Derriv. holdingOption5.002020-02-01Common Stock50625D
Derriv. holdingOption5.002021-03-01Common Stock31172D









←


 1 


→


 







db
 
 


















































Robert J. Greenberg - Second Sight Medical Products Insider Transactions | TipRanks   





Go ProLogin / Sign Up Follow✓Get Real Time TransactionsInsider DetailsRobert J. GreenbergSecond Sight Medical Products (EYES)President & CEO, DirectorRanked #16,677 out of 33,852 Insiders on TipRanksRobert J. Greenberg's PerformanceProfitable Transactions3 out of 6 profitable transactionsAverage  Return-1.4%Average return per transactionEach transaction is measured over a 1 Year3 Months1 Month period, and compared to No BenchmarkS&P 500Sector.How are Insiders Ranked? Insider Holdings 100.0% Second Sight Medical Products (EYES)$680KSee the Top Stocks by Insiders > Insider RolesSecond Sight Medical Products (EYES): President & CEO, DirectorSee the Top 25 Corporate Insiders > Most Profitable Insider TradeStock: Second Sight Medical Products (EYES)Transaction Type: Informative SellDates: Jun 06, 2016 - Jun 06, 2017Gain: +70.4%See the Latest Stocks Traded by Insiders > Robert J. Greenberg's Trading Historybased on Form 4 Follow✓Get Real Time TransactionsCompany NameInsider PositionHolding ValueLast TransactionLast Transaction  AmountLast Transaction DateEYESSecond Sight Medical ProductsPresident & CEO, Director$679,632Uninformative Sell$14,791.7Jun 07, 2017PLSEPulse BiosciencesDirector-Informative Sell$528,090.6May 10, 2017See All Insider Trading from Today >You May Also LikeMeet our Smart Portfolio. See what top analysts say about your stocks.Get a breakdown of the different strategies based on detected insider trading activity.Find the best performing Analyst in each sector. Follow them so you never miss a recommendation.Related LinksHow can I benefit from Insider Trading? >See the Top 25 Corporate Insiders >Go to Hot Stocks by Insiders >Find which stocks Insiders traded today >Become a TipRanks MemberGet the best Investing Tips & Hacks straight to your emailFree MembershipSubmitInsider Trading Daily NewsletterProfessional day-trading strategy based on predictive insider transactionsAnnual Return: +85.42%Learn More >Powered by
























